| Summary: | The current Common Drug Review (CDR) review was undertaken in response to a request from the drug plans that participate in the CDR review process that the use of levodopa/carbidopa intestinal gel (LCIG) in Parkinson disease (PD) be re-reviewed in light of the availability of new evidence. Therefore, for the current review, new clinical evidence that has become available since the CDR review in 2009 was considered for inclusion in a systematic review to assess the efficacy and harms of LCIG for the treatment of patients with advanced levodopa-responsive PD who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of PD medicinal products, and for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy tube required for administration
|
|---|